Scholar Rock

Scholar Rock

Biotechnology
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

$4.9B

Market Cap • 10/13/2026

2017

(9 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

19,4

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,1

EPS

—

Market Cap

Market Cap

4,9B

EV

4,6B

EV/Revenue

0

EV/EBITDA

-11,5

EV/EBIT

-11,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-7,1%

Total Yield

-7,1%

Payout

0%

Retained Earnings

-1,5B

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

12,5%

Capex/OCF

-0,1%

SBC/OCF

—

% PPE

1,9%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-100%

CAGR Op. Income 5Y

30,5%

CAGR Net Income 5Y

30,4%

CAGR EPS 5Y

0,9%

CAGR OCF 5Y

24%

Leverage

N.D./EBITDA

0,7

Debt/Equity

0%

Current Ratio

7

Quick Ratio

6,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium